Patent Application
20210228823
The present invention relates to catheters, specifically catheters with an additional channel for hyperbaric oxygen therapy along a patient's prostate.
It is believed that chronic prostatitis is one of the most common reasons why men visit urologists, even being characterized as the condition responsible for more outpatient visits than benign prostatic hypelplasia (“BPH”) or prostate cancer. At least one report states that 35-50% of men will be affected by prostatitis at some time in their life. The treatments conventionally used to treat this condition have been generally problematic; most of the treatments have provided little hope that the condition could be predictably treated in a manner which could successfully alleviate the pain experienced by a large percentage of these individuals. Indeed, prostatitis has been termed “a waste basket of clinical ignorance” because of the lack of knowledge about the basic epidemiology of the disease and also the diagnosis and treatments available for same. Unlike BPH, which occurs primarily in older men, prostatitis can occur in both younger (men in age groups of 18-50 (or younger)) and older men (over the age of 50), with the median reported patient age at about 40 years of age.
Various treatment protocols have been used to attempt to treat prostatitis. While category I may be managed successfully with wide spectrum antibiotics, patients having category II and III prostatitis have had lesser degrees of response success when treated with antibiotics. Other treatment regimens include other drugs such as alpha-blocker therapy (for obstructive voiding), and anti-inflammatory agents. In addition, or alternatively, the physician may suggest lifestyle changes such as diet (such as the reduction of the intake of caffeine), exercise, sexual activity, and/or supportive psychotherapy or “coping mechanisms”. In view of the above, there remains a need to provide improved and/or alternative treatments for chronic prostatitis. In recent studies, it is shown that hyperbaric oxygen therapy can effectively inhibit the growth of tumor cells. In addition, the injection of pure oxygen to the prostate will help stop bleeding for the cancerous prostate. Therefore, it is an object of the invention to provide a means of integrating hyperbaric oxygen therapy to both treat acute and chronic prostatitis.
The present invention is a urinary catheter with media injection channel suited for prostatitis treatment and therapy. The urinary catheter with media injection channel comprises a catheter body, an injection channel, and at least one injection aperture. In the preferred embodiment of the present invention, the urinary catheter may take the form of a foley catheter with an additional channel for oxygen injection to facilitate hyperbaric oxygen therapy along the patients prostate. The catheter body comprises a bladder opening, a balloon, and a utility port.
The bladder opening and the utility port are positioned terminally opposite to each other along the catheter body. In the preferred embodiment of the present invention, the bladder opening is the patient input end of the urinary catheter that allows a user to install the urinary catheter to the patient's bladder. The utility port of the urinary catheter serves as the region for urine extraction, oxygen delivery, or balloon inflation input. The balloon is positioned between the bladder opening and the utility port. At least one injection aperture is positioned adjacent to the balloon, opposite to the bladder opening. At least one injection aperture is distributed about the catheter body. The injection channel traverses from the utility port to the at least one injection aperture. The balloon, when inflated, stops the urinary catheter from coming out the patient's bladder. The balloon will also be used to block incoming oxygen from going into the patient's bladder. The injection channel serves as the oxygen injection channel that allows the user to inject pure oxygen directly to the prostate along the at least one injection aperture, facilitating hyperbaric oxygen therapy administration to the affected prostate.
All illustrations of the drawings are for the purpose of describing selected versions of the present invention and are not intended to limit the scope of the present invention. The present invention is to be described in detail and is provided in a manner that establishes a thorough understanding of the present invention. There may be aspects of the present invention that may be practiced or utilized without the implementation of some features as they are described. It should be understood that some details have not been described in detail in order to not unnecessarily obscure focus of the invention. References herein to “the preferred embodiment”, “one embodiment”, “some embodiments”, or “alternative embodiments” should be considered to be illustrating aspects of the present invention that may potentially vary in some instances, and should not be considered to be limiting to the scope of the present invention as a whole.
In reference to
The bladder opening 12 and the utility port 14 are positioned terminally opposite to each other along the catheter body 11, as shown in
The utility port 14 comprises an injection port 143, as shown in
The urinary catheter with media injection channel 1 further comprises an injection cavity 19, as shown in
The utility port 14 comprises a waste port 141, as shown in
The utility port 14 comprises an inflation port 142, as shown in
The urinary catheter with media injection channel 1 further comprises a balloon cavity 21, as shown in
Although the invention has been explained in relation to its preferred embodiment, it is to be understood that many other possible modifications and variations can be made without departing from the spirit and scope of the invention as hereinafter claimed.
The current application claims a priority to the U.S. Provisional Patent application Ser. No. 62/966,109 filed on Jan. 27, 2020.
| Number | Date | Country | |
|---|---|---|---|
| 62966109 | Jan 2020 | US |
